Literature DB >> 9381608

[Perioperative antibiotic prophylaxis in hip operations. Penetration into bone, capsule tissue and cartilage exemplified by cefuroxime].

A Katzer1, J V Wening, P Kupka, N M Meenen, K H Jungbluth.   

Abstract

The most serious complication of accident surgery is postoperative osteitis. At the same time, perioperative antibiotic prophylaxis is generally recommended in order to reduce the rate of infection in joint surgery. The criteria for the suitability of a substance as prophylaxis include inter alia the activity spectrum with respect to the expected microorganisms, its retention time in the body and its ability to penetrate the endangered tissue. In the present study, the systemic and local activity levels after a single i.v. dose of 1500 mg cefuroxime was investigated in relation to the time of administration in 30 patients who had to undergo total hip replacement owing to a medial fracture of the neck of the femur. The tissue and serum samples were analyzed by high pressure liquid chromatography (HPLC). The results show that the tissue levels of the intermediary cephalosporin after an i.v. single shot dose are on average still several times higher than the minimum inhibitory concentration (MIC) of the most frequent bacterium. Staphylococcus aureus, as late as 4 hours after application. The optimal time for the administration form selected was immediately prior to the operation and the concentrations measured suggest that several repeat doses of cefuroxime for short-term prophylaxis are not necessary.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9381608     DOI: 10.1007/bf02630223

Source DB:  PubMed          Journal:  Unfallchirurgie        ISSN: 0340-2649


  15 in total

1.  The penetration characteristics of cefazolin, cephalothin, and cephradine into bone in patients undergoing total hip replacement.

Authors:  B A Cunha; H R Gossling; H S Pasternak; C H Nightingale; R Quintiliani
Journal:  J Bone Joint Surg Am       Date:  1977-10       Impact factor: 5.284

2.  [Infection of bones and joints].

Authors:  C Burri; R Neugebauer
Journal:  Aktuelle Probl Chir Orthop       Date:  1989

Review 3.  Antimicrobial prophylaxis for arthroplasty and total joint replacement: discussion and review of published clinical trials.

Authors:  A F Heath
Journal:  Pharmacotherapy       Date:  1991       Impact factor: 4.705

4.  Serum and bone concentrations of cefuroxime in patients undergoing knee arthroplasty.

Authors:  D A Leigh
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

5.  Comparative pharmacokinetics of cefamandole, cefuroxime and cephradine during total hip replacement.

Authors:  A J Davies; R M Lockley; A Jones; M el-Safty; J C Clothier
Journal:  J Antimicrob Chemother       Date:  1986-05       Impact factor: 5.790

6.  [Determination of cephalothin levels in human tissues].

Authors:  R Plaue; K Fabricius; S Wysocki
Journal:  Chirurg       Date:  1974-06       Impact factor: 0.955

7.  [Hospital infections and problems of resistance today].

Authors:  A Encke; H Knothe
Journal:  Chirurg       Date:  1985-09       Impact factor: 0.955

8.  Bone concentrations of cefuroxime and cefamandole in the femoral head in 96 patients undergoing total hip replacement surgery.

Authors:  D A Leigh; J Marriner; D Nisbet; H D Powell; J C Church; K Wise
Journal:  J Antimicrob Chemother       Date:  1982-04       Impact factor: 5.790

9.  [Antibiotic prophylaxis in closed fractures is cost-effective if the possibility of a deep infection decreases through this by 0.25%].

Authors:  B A Albers; P Patka; H J Haarman; P J Kostense
Journal:  Ned Tijdschr Geneeskd       Date:  1993-06-12

10.  Antibiotics in bone tissues. Methodological and practical aspects.

Authors:  K Dornbusch
Journal:  Scand J Infect Dis Suppl       Date:  1978
View more
  1 in total

1.  [C-reactive protein. An independent risk factor for the development of infection after primary arthroplasty].

Authors:  T Pfitzner; D Krocker; C Perka; G Matziolis
Journal:  Orthopade       Date:  2008-11       Impact factor: 1.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.